Brief: Bellerophon Submits Investigational New Drug Application To Study Inhaled Nitric Oxide Therapy For COVID-19

Bellerophon Therapeutics

08/04/2020 13:32

April 8 (Reuters) - Bellerophon Therapeutics Inc  BLPH.O :
    * BELLEROPHON THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG
APPLICATION TO STUDY INOPULSE® INHALED NITRIC OXIDE THERAPY FOR
THE TREATMENT OF COVID-19
    * BELLEROPHON - STUDY, CALLED PULSE-CVD19-001, WILL EVALUATE
EFFICACY AND SAFETY OF INOPULSE IN PATIENTS WITH COVID-19 WHO
REQUIRE SUPPLEMENTAL OXYGEN.
    * BELLEROPHON - PULSE-CVD19-001 PROTOCOL AIMS TO ENROLL UP
TO 500
PATIENTS WITH COVID-19 WHO WILL BE TREATED WITH INOPULSE OR
STANDARD OF CARE
    * BELLEROPHON THERAPEUTICS INC - IN PARALLEL, CO HAS APPLIED
FOR
FEDERAL FUNDING, THROUGH BARDA AND NIH TO SUPPORT PROPOSED IND
STUDY.

Source text for Eikon:  ID:nGNX3JmJdk 
Further company coverage:  BLPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))